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Identity 
Other names: 5H9; BA2; P24; GIG2; MIC3; MRP-1; 
BTCC-1; DRAP-27; TSPAN29 
HGNC (Hugo): CD9 
Location: 12p13.31 
Local order: The CD9 gene is located between the 
VWF and the ATP5J2P5 genes. 
DNA/RNA 
Description 
The gene spans 38 kb of DNA, including a 10 kb intron 
separating the first two exons. CD9 encodes 8 exons, 
ranging from 63 to 109 base pairs. The coding 
sequence is highly conserved between species. The 
promoter contains neither TATA nor CAAT boxes, but 
does contain several consensus sequences for the 
binding of transcription factors (GATA, ETS, E2F, NF-
kB, AP2) as well as three putative Sp1 binding sites. 
Transcription 
The CD9 transcribed RNA has 1246 bases, of which 






CD9 is a member of the transmembrane 4 superfamily, 
also called the tetraspanin family. As other 
tetraspanins, CD9 is a cell-surface protein containing 
four hydrophobic transmembrane domains (indicated in 
green) and two extracellular domains (illustrated in 
violet). CD9 consists of 228 amino acids and weighs 
24-27 kDa. CD9 contains four small and highly 
conserved hydrophobic transmembrane domains (24-27 
amino acids); a small N-terminal (11 amino acids) and 
a C-terminal cytoplasmic (7 amino acids) tails, and a 
very small intracellular domain (4 amino acids). The 
remaining part of the protein is composed of two 
extracellular domains (also called loops; a small one of 
20 amino acids and a large one of 83 amino acids). 
Two disulfide bonds, generated by four well-conserved 
cysteine residues (C), stabilize the large extracellular 
domain. CD9 also contains a tetraspanin signature 
(amino acids 65-89) and a CCG motif (amino acids 152 
to 154), but lacks  
 
Genomic organisation of the CD9 gene on chromosome 12. 
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Structure of the CD9 protein. 
 
other motifs found on other tetraspanins (DW, PxSc3, 
Gc4). 
Expression 
CD9 is expressed by a variety of hematopoietic and 
epithelial cells. It is transiently expressed during 
development of spinal motoneurons and other fetal 
nervous system sites, as well as in hematopoietic 
development. CD9 is glycosylated (the glycosylation 
site is in the first extracellular loop unlike most 
glycosylated tetraspanins where the site is located in 
the second extracellular loop) and acylated. CD9 is also 
phosphorylated on tyrosine following B-cell activation.  
CD9 is up-regulated on activated B and T lymphocytes. 
Localisation 
In normal cells, CD9 localizes mainly in the 
membranes while in cancer cells the protein may also 
be detected throughout the cytoplasm. 
Function 
CD9 can interact or form complexes with many other 
proteins, including other tetraspanins, integrins, EWI 
molecules, TGF-a, diphtheria toxin receptor, receptor 
tyrosine kinase, pregnancy specific glycoproteins, and 
proteins of the immune system such as MHC class II 
molecules and members of the Ig superfamily. 
Moreover, probably because of its localization in the 
cell membrane, CD9 is involved in platelet activation 
and aggregation, as well as in cell adhesion, spreading, 
cell motility and tumor metastasis. CD9 also regulates 
paranodal junction formation, and is required for 
gamete fusion. Furthermore, CD9 promotes muscle cell 
fusion and supports myotube maintenance. 
Homology 
Although there are variations in the amino acid 
sequence in the extracellular loops, the CD9 protein 
sequence is very well conserved between species (90% 
between human, mice and rat). CD9 share also some 




Although no genomic CD9 mutation has been reported, 
in prostate cancer, there is mention of cDNA mutation 
compatible with an RNA editing mechanism. So far, 
CD9 has never been implicated in gene fusion that 




Decreased expression of the CD9 protein has been 
associated with many types of cancer. 
Disease 
- Expressed in 90% of non-T cell acute lymphoblastic 
leukemia cells and in 50% of chronic lymphocytic 
leukemia and acute myeloblastic leukemia. 
- Expression inversely correlated with metastatic 
potential of melanoma. 
- Expression suppresses motility and metastasis of 
carcinoma cells. 
- Reduction of expression correlated with poor 
prognosis in breast, lung and colon carcinomas. 
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